Login to Your Account



Regulatory Filings to Begin at Year-End

Phase III UMEC/VI Studies a Win for Theravance/GSK

By Marie Powers
Staff Writer

Tuesday, July 3, 2012
Regulatory filings appear to be the next step for the LAMA/LABA bronchodilator combination of umeclidinium bromide (UMEC, or GSK573719) and vilanterol (VI), under development by GlaxoSmithKline plc and longtime partner Theravance Inc. The companies reported top-line results early Monday indicating the first four of seven Phase III studies of the investigational therapy showed superiority against both placebo and current standard of care in chronic obstructive pulmonary disease (COPD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription